GENEVA--(BUSINESS WIRE)--Selexis SA and Berkeley Lights, Inc. today announced a collaboration around the acquisition of Berkeley Lights’ Beacon ® optofluidic platform. The partners will leverage the ...

GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest ...

Hemogenyx Pharmaceuticals and Selexis SA ("Selexis") will leverage Selexis' SUREtechnology Platform™ of protein expression technologies and modular workflows to advance the Company's acute myeloid ...

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, ...

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage. On June 29, 2021, Selexis and KBI Biopharma (KBI), both JSR Life ...

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with technologies for drug discovery, cell-line development and scale-up to manufacturing of therapeutic proteins. For ...

Monoclonal antibodies developer Xencor has extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements. Under these agreements, Xencor gains nonexclusive license ...

GENEVA, Jan. 9, 2012 /PRNewswire/ -- Selexis SA announced today the appointment of Yemi Onakunle, Ph.D., M.B.A. as Vice President of Strategic and Market Development. Dr. Onakunle will report directly ...

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announces that it ...

Industry Expert with 20+ Years' Experience in Biopharmaceutical Drug Development and Manufacturing Now Leading Company's Global Corporate and Business Development Efforts Selexis SA, a JSR Life ...

Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, has announced the launch of a novel selection method to screen and ...

Merus and Selexis will combine technology platforms to produce colorectal cancer combination therapy. Merus, which develops bispecific antibody therapeutics to treat cancer patients, and Selexis, ...